Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder
Guardant Health, Inc. (Nasdaq: GH) has completed a public offering of 7.7 million shares of common stock, priced at $102.00 per share, including 700,000 shares from the underwriter's option. Notably, Guardant Health did not sell any shares nor receive proceeds from this offering, which was conducted by SoftBank Investment Advisers. The offering was made under an automatic shelf registration statement filed with the SEC, which became effective upon filing. J.P. Morgan Securities LLC served as the book-running manager for this offering.
- Proceeds from the offering will bolster the company’s financial positioning as it advances its oncology solutions.
- Shareholder dilution may occur since the offering involved shares sold by SoftBank Investment Advisers.
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the closings of an underwritten public offering of 7,700,000 shares of its common stock, which includes full exercise of the underwriter’s option to purchase 700,000 shares, at a public offering price of
Guardant Health did not sell any of its shares in the offering and did not receive any of the proceeds from the sale of shares in the offering by SoftBank Investment Advisers.
J.P. Morgan Securities LLC acted as sole book-running manager of the offering.
The public offering was made pursuant to an automatic shelf registration statement on Form S-3 that was filed by Guardant Health with the U.S. Securities and Exchange Commission (the “SEC”) and automatically became effective upon filing. A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained by contacting: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
Source: Guardant Health, Inc.
